|

Discontinuation of CDK4/6 inhibitor Abemaciclib Clinical Trials

1 actively recruiting trial

Also known as: Study treatment

Pipeline

Phase 2: 1

Top Sponsors

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest1

Indications

  • Breast Cancer1
  • Cancer1

Other1 trial

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.